摘要
目的:探讨司库奇尤单抗治疗中重度斑块状银屑病的效果及对免疫功能的影响。方法:选取2022年1-6月通辽市医院收治的100例中重度斑块状银屑病患者,使用随机数字表法将其分为观察组(n=50)及对照组(n=50)。对照组予以阿维A胶囊联合他扎罗汀凝胶治疗,观察组予以司库奇尤单抗治疗。对比两组总有效率、炎症因子水平、免疫功能指标水平、皮肤组织中程序性死亡蛋白-1(PD-1)及程序性死亡蛋白配体-1(PD-L1)水平、不良反应发生率。结果:观察组总有效率(96.00%)高于对照组(84.00%),不良反应发生率(4.00%)低于对照组(18.00%),差异均有统计学意义(P<0.05);治疗后,两组肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)、白细胞介素-17(IL-17)、白细胞介素-23(IL-23)水平均较治疗前降低,且观察组均低于对照组(P<0.05);治疗后,两组CD3^(+)、CD4^(+)水平均较治疗前上升,观察组均高于对照组,CD8^(+)水平均较治疗前下降,观察组低于对照组(P<0.05);治疗后,两组PD-1 mRNA及PD-L1 mRNA水平均较治疗前降低,且观察组均低于对照组(P<0.05)。结论:司库奇尤单抗治疗中重度斑块状银屑病效果优异,可有效缓解患者临床症状,减轻炎症反应,提高免疫功能,抑制皮损组织中异常上调的PD-1及PD-L1水平,减少不良反应的发生,安全有效。
Objective: To investigate the effect of Secukinumab in the treatment of moderate and severe plaque psoriasis and its influence on immune function. Method: A total of 100 patients with moderate and severe plaque psoriasis treated in Tongliao City Hospital from January 2022 to June 2022 were divided into an observation group(n=50) and a control group(n=50) using random number table method. The control group was treated with Acitretin Capsules combined with Tazarotene Gel, and the observation group was treated with Secukinumab. The total effective rate, inflammation factors levels, immune function indexes levels, programmed death-1(PD-1) and programmed death ligand-1(PD-L1) levels in skin tissue and the incidence of adverse reactions between the two groups were compared. Result: The total effective rate of the observation group(96.00%) was higher than that of the control group(84.00%), and the incidence of adverse reactions(4.00%) was lower than that of the control group(18.00%), the differences were statistically significant(P<0.05). After treatment, the levels of tumor necrosis factor-α(TNF-α), interleukin-2(IL-2), interleukin-17(IL-17) and interleukin-23(IL-23) in the two groups were lower than those before treatment and the levels in the observation group were lower than those in the control group(P<0.05).After treatment, the levels of CD3^(+), CD4^(+)in the two groups were higher than those before treatment and the levels in the observation group were higher than those in the control group, the levels of CD8^(+)in the two groups were lower than those before treatment and the level in the observation group was lower than that in the control group(P<0.05). After treatment, PD-1 mRNA and PD-L1 mRNA levels in the two groups were lower than those before treatment and the levels in the observation group were lower than those in the control group(P<0.05). Conclusion: Secukinumab has excellent effect in the treatment of moderate and severe plaque psoriasis, and can effectively relieve clinical symptoms of patients, reduce inflammatory reactions, improve immune function, inhibit abnormally increased PD-1 and PD-L1levels in skin lesion tissues, and reduce the occurrence of adverse reactions, it is safe and effective.
作者
陈紫津
CHEN Zijin(Tongliao City Hospital,Inner Mongolia,Tongliao 028000,China)
出处
《中国医学创新》
CAS
2023年第2期55-59,共5页
Medical Innovation of China
